Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Positive results from new analyses of denosumab Phase 3 trials

Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.

5 Jun 2010

USC to present promising new findings in cancer research at 2010 ASCO

Faculty at the University of Southern California (USC) and USC Norris Comprehensive Cancer Center will present promising new findings in a number of cancer research areas at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from June 4-8.

5 Jun 2010

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Amgen today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic cancer. The study, which also included a separate arm of conatumumab plus gemcitabine, is being presented in a Poster Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that data from a recent clinical trial of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

2 Jun 2010

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

2 Jun 2010

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators from the University of Pennsylvania's Abramson Cancer Center at the 2010 meeting of the American Society of Clinical Oncology June 4 through 8.

2 Jun 2010

Hitachi Software, OriGene announce co-marketing agreement

Hitachi Software Engineering America, Ltd. and OriGene Technologies, Inc. today announced a co-marketing agreement to jointly promote OriGene's multiplex assays built on Luminex xMAP/Bio-Plex technology and Hitachi Software's MasterPlex software suite for analysis and reporting of multiplex assay data.

29 May 2010

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").

28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

27 May 2010

FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging

Repligen Corporation announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read).

27 May 2010

Experimental Hendra virus treatment offered to mother and daughter

After recent reports of a horse being put down for being infected with the deadly Hendra virus, new reports of an experimental treatment have surfaced. At Queensland's Sunshine Coast a mother and daughter duo, Rebecca Day and her 12 year old girl Mollie, who had been exposed to the virus, have been offered the experimental treatment.

27 May 2010

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the receipt of $5 million from Nycomed for reaching a clinical milestone under the license and collaboration agreement, entered into on July 11, 2008.

26 May 2010

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Agilent Technologies Inc. today introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

25 May 2010

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.

24 May 2010

Immunome announces completion of financing by BioAdvance

Immunome, a discovery-stage antibody platform company focused on life-threatening infectious diseases, announced today the completion of a financing by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. The funding round also included private investors.

24 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Monoclonal Antibody News and Research

Further Reading

Positive results from new analyses of denosumab Phase 3 trials

USC to present promising new findings in cancer research at 2010 ASCO

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Data on ImmunoCellular Therapeutics' ICT-107 for GBM to be presented at 46th ASCO

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Hitachi Software, OriGene announce co-marketing agreement

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging

Experimental Hendra virus treatment offered to mother and daughter

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Immunome announces completion of financing by BioAdvance

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News